TYRATECH • ANNUAL REPORT 2014 • PAGE 11
Regulatory investigations and litigation may lead to fines or
other penalties
There is a risk that TyraTech would face regulatory investigation
and potentially litigation if there were data errors in the submission
documents or if new data came out that impacted the claims or
safety profile of the product.
DIRECTORS
The directors who served during 2014 were as follows:
A.J. Reade
B.M. Riley
J. Hills
E. Wintemute
B. Jactel
BIOGRAPHIES OF THE DIRECTORS FOLLOW:
Alan Reade was appointed on 25 May 2007 as a Non-Executive
Director. In 2010 he became the Executive Chairman and then,
in June 2013, he became the Non-Executive Chairman. He is
owner of Global Strategy Expression Limited, a consulting and
advisory services business in the life sciences industry. From 2000
until his retirement in 2005, he served as Executive Chairman
of Merial Limited, a leading animal health company and joint
venture between Merck & Co. Inc. and Sanofi-Aventis. Earlier in
his career he was head of global integration at Aventis, where he
was in charge of merger integration. Prior to that, he was Chief
Executive Officer at Rhone-Poulenc Agro Inc. and member of the
Global Executive Committee. He is Chairman of the Nomination
Committee and a member of the Audit Committee.
Barry Riley (Non-Executive Director) was appointed on 25 May
2007. After qualifying as a Chartered Accountant, he joined the
Bowater Organization, where he had responsibility for the finance
function at several operations. From there he moved to FMC
Corporation, the U.S. conglomerate where he had finance and
general management responsibilities for a specialty chemical
operation, and also oversaw the head office finance function
for all UK operations. He joined Proteus International PLC in 1995
as Finance Director and was closely involved in the merger with
Therapeutic Antibodies Inc. in 1999, which became Protherics
PLC where he was Finance Director until 2007. He is chairman
of the Audit Committee and a member of the Remuneration
Committee.
James Hills (Non-Executive Director) was appointed on 09 July
2010. Mr. Hills spent the early portion of his career with The Gillette
Company and Coca Cola USA where he held senior positions
in both sales and brand management. Later, he was a 50%
partner and Chief Executive Officer of Weatherly Consumer
Products Inc., a company which developed, branded and
marketed specialty fertilizers in North America and Europe, under
the Jobe's brand name. Following the sale of that business in
1996, he started Gulfstream Home and Garden, a company
which marketed lawn and garden insecticides under the Sevin
brand name in the U.S. He sold that business in 2005 following
nearly ten years of rapid growth. Mr. Hills is chairman of the
Remuneration Committee and a member of the Nomination
and Audit Committees.
Bruno Jactel, D.V.M. was appointed as Chief Executive Officer
of TyraTech effective 10 January 2013. Dr. Jactel spent 12 years
at Merial Limited, the $2.6 billion revenue generating Animal
Health subsidiary of the Sanofi Group, most recently serving as
combined Chief Strategy Officer and Chief Marketing Officer. As
head of commercial operations in Europe, Dr. Jactel developed
successful growth strategies in both OTC and professional
channels. Prior to working at Merial, Dr. Jactel was Deputy Minister
for Economic and Commercial Affairs at the French Embassy
in Washington, D.C. He was also a recent founder and board
member of Hypercell Technologies LLC, an early-stage biotech
company developing therapeutic solutions to serious infectious
animal disease. Dr. Jactel is a Doctor of Veterinary Medicine and
has a Masters in Economic Sciences from the Sorbonne University
in Paris. He graduated from the École Nationale d'Administration,
Paris in 1993.
Eric Wintemute was appointed to the Board as a Non-Executive
Director on 20 June 2013. Mr. Wintemute was elected to the post
of AMVAC's President and American Vanguard Corporation's
Chief Executive Officer in mid-1994. Mr. Wintemute had joined
AMVAC in January 1994 as Executive Vice President, Chief
Operating Officer, and a member of the Board of Directors
